Cargando…

Cerebrospinal Fluid Penetration of Ceftolozane-Tazobactam in Critically Ill Patients with an Indwelling External Ventricular Drain

The aim of this study was to describe the pharmacokinetics of ceftolozane-tazobactam in plasma and cerebrospinal fluid (CSF) of infected critically ill patients. In a prospective observational study, critically ill patients (≥18 years) with an indwelling external ventricular drain received a single...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sime, Fekade B., Lassig-Smith, Melissa, Starr, Therese, Stuart, Janine, Pandey, Saurabh, Parker, Suzanne L., Wallis, Steven C., Lipman, Jeffrey, Roberts, Jason A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2020
Materias:	Clinical Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927828/ https://www.ncbi.nlm.nih.gov/pubmed/33077655 http://dx.doi.org/10.1128/AAC.01698-20

Ejemplares similares

Population Pharmacokinetics of Unbound Ceftolozane and Tazobactam in Critically Ill Patients without Renal Dysfunction
por: Sime, Fekade B., et al.
Publicado: (2019)

A Population Pharmacokinetic Model-Guided Evaluation of Ceftolozane-Tazobactam Dosing in Critically Ill Patients Undergoing Continuous Venovenous Hemodiafiltration
por: Sime, Fekade B., et al.
Publicado: (2019)

Pharmacokinetics of Intravenous Posaconazole in Critically Ill Patients
por: Sime, Fekade B., et al.
Publicado: (2018)

Ceftolozane-tazobactam in nosocomial pneumonia
por: Candel, Francisco Javier, et al.
Publicado: (2022)

Exposure–Efficacy Analyses Support Optimal Dosing Regimens of Ceftolozane/Tazobactam in Participants with Hospital-Acquired/Ventilator-Associated Bacterial Pneumonia in ASPECT-NP
por: Gao, Wei, et al.
Publicado: (2022)

Population pharmacokinetics of total and unbound concentrations of intravenous posaconazole in adult critically ill patients
por: Sime, Fekade B., et al.
Publicado: (2019)

Erratum: Ceftolozane-tazobactam in nosocomial pneumonia
por: FJ, Candel, et al.
Publicado: (2022)

1319. Pharmacokinetics of Ceftolozane/Tazobactam in Patients with Burns
por: Hall, Ronald G, et al.
Publicado: (2020)

Ceftolozane-tazobactam: When, how and why using it?
por: López, Inmaculada, et al.
Publicado: (2021)

Ceftolozane-Tazobactam Combination Therapy Compared to Ceftolozane-Tazobactam Monotherapy for the Treatment of Severe Infections: A Systematic Review and Meta-Analysis
por: Fiore, Marco, et al.
Publicado: (2021)

Plasma and Cerebrospinal Fluid Therapeutic Drug Monitoring of Ceftolozane and Tazobactam During Treatment of Multidrug-Resistant Pseudomonas aeruginosa Meningitis
por: McCreary, Erin K, et al.
Publicado: (2020)

Deciphering the Evolution of Cephalosporin Resistance to Ceftolozane-Tazobactam in Pseudomonas aeruginosa
por: Barnes, Melissa D., et al.
Publicado: (2018)

Chemical Stability of Ceftolozane/Tazobactam in Polyvinylchloride Bags and Elastomeric Pumps
por: Terracciano, Joseph, et al.
Publicado: (2017)

Ceftolozane/Tazobactam Dosing Requirements Against Pseudomonas aeruginosa Bacteremia
por: Ruiz, Jesus, et al.
Publicado: (2020)

Ceftolozane/Tazobactam Resistance and Mechanisms in Carbapenem-Nonsusceptible Pseudomonas aeruginosa
por: Teo, Jocelyn Qi-Min, et al.
Publicado: (2021)

Ceftolozane–tazobactam- and ceftazidime–avibactam-resistant Pseudomonas aeruginosa mastoiditis
por: Jacobs, Jeremy, et al.
Publicado: (2020)

Comparison between meropenem and ceftolozane/tazobactam: possible influence of CRRT
por: Honore, Patrick M., et al.
Publicado: (2022)

A Real-world Multicenter Outpatient Experience of Ceftolozane/Tazobactam
por: Van Anglen, Lucinda J, et al.
Publicado: (2023)

Probability of Target Attainment Analyses to Inform Ceftolozane/Tazobactam Dosing Regimens for Patients With Hospital‐Acquired or Ventilator‐Associated Bacterial Pneumonia and End‐Stage Renal Disease Receiving Intermittent Hemodialysis
por: Feng, Hwa‐Ping, et al.
Publicado: (2022)

Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections
por: Goodlet, Kellie J, et al.
Publicado: (2016)

Failure of ceftolozane‐tazobactam salvage therapy in complicated pneumonia with lung abscess
por: Lewis, Paul O., et al.
Publicado: (2018)

Use of Ceftolozane/Tazobactam in a Case of Septic Shock by Puerperal Sepsis
por: Pezzi, Mario, et al.
Publicado: (2019)

Clinical and Safety Evaluation of Continuously Infused Ceftolozane/Tazobactam in the Outpatient Setting
por: Jones, Bruce M, et al.
Publicado: (2020)

Real-world use of ceftolozane/tazobactam: a systematic literature review
por: Puzniak, Laura, et al.
Publicado: (2021)

Ceftolozane/tazobactam for the treatment of bacteremia: a systematic literature review (SLR)
por: Khankhel, Z. S., et al.
Publicado: (2022)

Ceftolozane/tazobactam heteroresistance in cystic fibrosis-related Pseudomonas aeruginosa infections
por: Monogue, Marguerite L, et al.
Publicado: (2023)

Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia
por: Caro, Luzelena, et al.
Publicado: (2020)

Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and β-lactamase-inhibitor combination
por: Hong, Mai-Chi, et al.
Publicado: (2013)

Profile of ceftolozane/tazobactam and its potential in the treatment of complicated intra-abdominal infections
por: Skalweit, Marion J
Publicado: (2015)

Critical evaluation of ceftolozane–tazobactam for complicated urinary tract and intra-abdominal infections
por: Giancola, Stephanie E, et al.
Publicado: (2016)

Ceftolozane-tazobactam for the Treatment of Multi Drug-resistant Pseudomonas aeruginosa (MDRPA) Infections
por: Molnar, Esther, et al.
Publicado: (2017)

Treatment of Polymicrobial Osteomyelitis with Ceftolozane-Tazobactam: Case Report and Sensitivity Testing of Isolates
por: Jolliff, Jeffrey C., et al.
Publicado: (2016)

2200. Cost-effectiveness of Ceftolozane/Tazobactam for Treating Ventilated Nosocomial Bacterial Pneumonia
por: Naik, Jaesh, et al.
Publicado: (2019)

2248. Clinical and Microbiological Outcomes Associated with Real-World Use of Ceftolozane/Tazobactam
por: Cabrera, Nicolo, et al.
Publicado: (2019)

1222. Ceftolozane-Tazobactam Heteroresistance in Cystic Fibrosis Related Pseudomonas aeruginosa Infections
por: Sanders, James, et al.
Publicado: (2021)

Traumatic cerebrospinal fluid oculorrhea managed with an external ventricular drain
por: Sheth, Aniruddha A, et al.
Publicado: (2018)

1612. Evaluation of the Use of Ceftolozane/Tazobactam for the Treatment of ESBL-producing Enterobacterales Infections Using International Data from SPECTRA (Study of Prescribing Patterns and Effectiveness of Ceftolozane/Tazobactam Real World Analysis)
por: Soriano, Alex, et al.
Publicado: (2020)

Efflux Pump AcrAB Confers Decreased Susceptibility to Piperacillin–Tazobactam and Ceftolozane–Tazobactam in Tigecycline-Non-Susceptible Klebsiella pneumoniae
por: Li, Junjie, et al.
Publicado: (2020)

In Vitro Activity of Ceftolozane/Tazobactam vs Nonfermenting, Gram-Negative Cystic Fibrosis Isolates
por: Forrester, Jeanne B, et al.
Publicado: (2018)

415 In Vitro Potency of Ceftolozane/Tazobactam against Pseudomonas aeruginosa Displaying Multidrug Resistance
por: Sutherland, Christina, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_llrg1vv1m4cpmchb3oe8fkofhe